Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I1 receptor

European Journal of Pharmacology

Volumn 599, Issue 1-3, 2008, Pages 18-23

  Gao, Yan ^a   Li, Fei ^a   Wu, Ning ^a   Su, Rui Bin ^a   Liu, Ying ^a   Lu, Xin Qiang ^a   Liu, Yin ^a   Li, Jin ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Agmatine; Down regulation of opioid receptor; Imidazoline I1 receptor; Internalization of opioid receptor; IRAS

Indexed keywords

AGMATINE; EFAROXAN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; IMIDAZOLINE I1 RECEPTOR; MU OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; DRUG TOLERANCE; GENETIC TRANSFECTION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

AGMATINE; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG TOLERANCE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; IMIDAZOLINE RECEPTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTORS, OPIOID, MU; RNA, MESSENGER; TRANSFECTION;

EID: 54949096500     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.020     Document Type: Article

References (39)

1. Aricioglu-Kartal F., and Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci. 61 (1997) 1775-1781
2. Bailey C.P., and Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol. 5 (2005) 60-68
3. Bernstein M.A., and Welch S.P. μ-opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic Morphine tolerance. Mol. Brain Res. 55 (1998) 237-242
4. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., and Caron M.G. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 408 (2000) 720-723
5. Bousquet P., Feldman J., and Schwartz J. Central cardiovascular effects of the a-adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230 (1984) 232-236
6. Claing A., Laporte S.A., Caron M.G., and Lefkowitz R.J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66 (2002) 61-79
7. Dontenwill M., Pascal G., Piletz J.E., Chen M., Baldwin J., Ronde P., Dupuy L., Urosevic D., Greney H., Tadeda K., and Bousquet P. IRAS, the human homologue of nischarin, prolongs survival of transfected PC12 cell. Cell Death Differ. 10 (2003) 933-935
8. Dontenwill M., Piletz J.E., Chen M., Baldwin J., Pascal G., Ronde P., Dupuy L., Greney H., Takeda K., and Bousquetd P. IRAS is an anti-apoptotic protein. Ann. N. Y. Acad. Sci. 1009 (2003) 400-412
9. Dupuy L., Urosevic D., Greney H., Quaglia W., Pigini M., Brasili L., Dontenwill M., and Bousquet P. I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. Cell Death Differ. 11 (2004) 1049-1052
10. Finn A.K., and Whistler J.L. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32 (2001) 829-839
11. Fraser C.M., Arakawa S., McCOmbie R.W., and Venter C.J. Cloning, sequence analysis, and permanent expression of a human α2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J. Biol. Chem. 264 (1989) 11754-11761
12. Goodman C.B., Emilien B., Becketts K., Cadet J.L., and Rothman R.B. Down-regulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and Morphine. Peptides 17 (1996) 389-397
13. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296 (1996) 17-22
14. Law P.Y., Hom D.S., and Loh H.H. Opiate receptor down-regulation and desensitization in neuroblastoma X glioma NG108-15 hybrid cells are two separate cellular adaptation processes. Mol. Pharmacol. 24 (1983) 413-424
15. Law P.Y., Erickson L.J., El-Kouhen R., Dicker L., Solberg J., Wang W., Miller E., Burg A.L., and Loh H.H. Receptor density and recycling affect the rate of agonist-induced desensitization of m-opioid receptor. Mol. Pharmcol. 58 (2000) 388-398
16. Li J., Li X., Pei G., and Qin B.Y. Agmatine inhibited tolerance to and dependence on morphine in guinea pig ileum in vitro. Acta Pharmacol. Sin. 19 (1998) 564-568
17. Li J., Li X., Pei G., and Qin B.Y. Analgesic effect of agmatine and its enhancement on morphine analgesia in mice and rats. Acta Pharmacol. Sin. 20 (1999) 81-85
18. Li J., Li X., Pei G., and Qin B.Y. Effects of agmatine on tolerance to and substance dependence on morphine in mice and rats. Acta Pharmacol. Sin. 20 (1999) 232-238
19. Li F., Wu N., Su R.B., Zheng J.Q., Xu B., Lu X.Q., Cong B., and Li J. Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein. J. Cell. Biochem. 98 (2006) 1615-1628
20. Liu J.G., and Anand K.J. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain. Res. Rev. 38 (2001) 1-19
21. McQuay H. Opioids in pain management. Lancet 353 (1999) 2229-2232
22. Morgan A.D., Campbell U.C., Fons R.D., and Carroll M.E. Effect of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol. Biochem. Behav. 72 (2002) 873-880
23. Petruzzi R., Ferraro T.N., Kurschner V.C., Golden G.T., and Berrettini W.H. The effects of repeated morphine exposure on mu opioid receptor number and affinity in C57BL/6J and DBA/2J mice. Life Sci. 61 (1997) 2057-2064
24. Piletz J.E., Ivanov T.R., Sharp J.D., Ernsberger P., Chang C.H., Pickard R.T., Gold G., Roth B., Zhu H., Jones J.C., Baldvin J., and Reis D.J. Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA. Cell Biol. 19 (2000) 319-329
25. Piletz J.E., Wang G., and Zhu H. Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue. Ann. N. Y. Acad. Sci. 1009 (2003) 392-399
26. Qiu Y., Law P.Y., and Loh H.H. μ-Opioid receptor desensitization, role of receptor phosphorylation, internalization, and resensitization. J. Biol. Chem. 278 (2003) 36733-36739
27. Ruiz-Durantez E., Llorente J., Ulibarri I., Pineda J., and Ugedo L. Agmatine-morphine interaction on nociception in mice. Ann. N. Y. Acad. Sci. 1009 (2003) 133-136
28. Stafford K., Gomes A.B., Shen J., and Yoburn B.C. μ-Opioid receptor down-regulation contributes to opioid tolerance in vivo. Pharmacol. Biochem. Behav. 69 (2001) 233-237
29. Su R.B., Li J., and Qin B.Y. Biphasic opioid function modulator: agmatine. Pharmacology 24 (2003) 631-636
30. Uzbay I.T., Yesilyurt O., Celik T., Ergun H., and Isimer A. Effect of agmatine on ethanol withdrawal syndrome in rats. Behav. Brain Res. 107 (2000) 153-159
31. Whistler J.L., Chuang H.H., Chu P., Jan L.Y., and Zastrow M.V. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23 (1999) 737-746
32. Williams J.T., Christie M.J., and Manzoni O. Cellular and synaptic adaptations. mediating opioid dependence. Physiol. Rev. 81 (2001) 299-343
33. Wu N., Su R.B., Zhao Y., Xu B., Liu Y., Lu X.Q., and Li J. Role of I1-imidazoline receptor on Naloxone-induced cAMP overshooting in chronic morphine treated CHO-μ/I1 cells. Biochem. Pharmcol. 70 (2005) 1079-1087
34. 1 receptor. Eur. J. Pharmacol. 548 (2006) 21-28
35. Yu S.S., Lefkowitz R.J., and Hausdorff W.P. Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J. Biol. Chem. 268 (1993) 337-341
36. Zhang F., Li J., Li J.G., and Liu-Chen L.Y. (-)U50,488H [(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide] induces internalization and down-regulation of the human, but not the rat, κ-opioid receptor: structural basis for the differential regulation. J. Pharmacol. Exp. Ther. 302 (2002) 1184-1192
37. Zhang Q., Purohit V., and Yoburn B.C. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord. Synapse 56 (2005) 123-128
38. Zhu J., Luo L.Y., Li J.G., Chen C., and Liu-Chen L.Y. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPγS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282 (1997) 676-684
39. Zuo Z.Y. The role of opioid receptor internalization and β-arrestins in the development of opioid tolerance. Anesth. Analg. 101 (2005) 728-734